Ivermectin as a potential therapeutic strategy for glioma

Area of Science:

• Pharmacology
• Oncology
• Drug Discovery

Background:

• Ivermectin (IVM) is a semi-synthetic macrolide parasiticide recognized for its efficacy against internal and external parasites.
• The development of IVM led to the 2015 Nobel Prize in Physiology or Medicine for Satoshi Omura and William C. Campbell.
• Emerging research indicates that IVM exhibits significant antitumor properties against various cancer cell types.

Purpose of the Study:

• To review the mechanisms by which Ivermectin (IVM) suppresses glioma growth.
• To explore the potential of IVM as a novel anticancer agent for glioma treatment.
• To discuss the challenges and future prospects of using IVM in cancer therapy.

Main Methods:

• Literature review of preclinical studies and scientific investigations.
• Analysis of research detailing Ivermectin's molecular targets and signaling pathways in cancer cells.
• Synthesis of findings on Ivermectin's antitumor effects, particularly in glioma models.

Main Results:

• Ivermectin (IVM) demonstrates the ability to inhibit the proliferation of diverse cancer cells, including glioma.
• IVM exerts its antitumor effects through multiple mechanisms, including targeting tumor-specific proteins and modulating signaling pathways.
• IVM can induce programmed cell death (apoptosis) in cancer cells.

Conclusions:

• Ivermectin (IVM) possesses considerable potential as a novel therapeutic agent for glioma.
• Further research is warranted to fully understand the mechanisms and optimize the clinical application of IVM in oncology.
• Addressing challenges in drug delivery and clinical efficacy will be crucial for translating IVM's anticancer potential into effective treatments.